Geode Capital Management LLC Grows Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)

Geode Capital Management LLC boosted its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 7.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 714,956 shares of the company's stock after purchasing an additional 52,362 shares during the quarter. Geode Capital Management LLC owned about 1.36% of Janux Therapeutics worth $38,288,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of JANX. Avanza Fonder AB purchased a new stake in shares of Janux Therapeutics in the 4th quarter worth approximately $139,000. Meeder Asset Management Inc. purchased a new stake in Janux Therapeutics during the 4th quarter valued at about $159,000. Chicago Capital LLC bought a new stake in Janux Therapeutics during the 4th quarter valued at about $230,000. Legato Capital Management LLC purchased a new position in Janux Therapeutics in the fourth quarter worth about $347,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Janux Therapeutics during the third quarter valued at approximately $317,000. Hedge funds and other institutional investors own 75.39% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on JANX. HC Wainwright reaffirmed a "buy" rating and set a $70.00 target price on shares of Janux Therapeutics in a report on Monday, March 3rd. Wedbush restated an "outperform" rating and issued a $76.00 price objective (up from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Scotiabank lowered their target price on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research report on Friday, February 28th. William Blair reaffirmed an "outperform" rating on shares of Janux Therapeutics in a research report on Friday, January 10th. Finally, Lifesci Capital raised shares of Janux Therapeutics to a "strong-buy" rating in a report on Friday, December 27th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $95.25.

Insiders Place Their Bets

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,334 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $32.15, for a total value of $107,188.10. Following the completion of the sale, the insider now owns 82,139 shares of the company's stock, valued at $2,640,768.85. This trade represents a 3.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ra Capital Management, L.P. bought 341,742 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were acquired at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the transaction, the director now directly owns 9,658,988 shares of the company's stock, valued at approximately $295,951,392.32. This trade represents a 3.67 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 29.40% of the stock is owned by insiders.

Janux Therapeutics Price Performance

Shares of JANX stock traded up $1.00 during trading hours on Friday, hitting $29.69. The stock had a trading volume of 367,166 shares, compared to its average volume of 854,854. The stock has a market capitalization of $1.75 billion, a price-to-earnings ratio of -25.38 and a beta of 3.27. Janux Therapeutics, Inc. has a one year low of $22.52 and a one year high of $71.71. The stock's 50-day moving average price is $30.67 and its two-hundred day moving average price is $43.59.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, equities research analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.